HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

No randomized trial shows ezetimibe alone lowers heart attack or stroke risk

Louis Nervegna · Aug 13, 2026 · ♥ 13 reactions · 22 comments · original Facebook post
PCSK9, ezetimibe & newer drugsStatins
AI summary & key facts

Louis warns against stopping a statin for ezetimibe monotherapy because no randomized trial has shown ezetimibe alone reduces events. It is usually prescribed in addition to statins.

Thinking of stopping your statin and switching to ezetimibe?

You’re taking a big risk…

No randomized trial has ever shown that ezetimibe by itself lowers risk of heart attacks and strokes.

This is why most cardiologists hesitate to prescribe ezetimibe as a monotherapy. They usually prescribe it in addition to statins, not in place of them.

Reference for video clip:
facebook.com/share/v/19AGc6yVcz

#ezetimibeHD #statinsHD #statinsezetimibeHD #ezetimibemonotherapyHD

← newer: No trial has shown PCSK9 inhibitors lower heart attack risk older: Esselstyn's showcase angiogram followed a heart attack, over →